State 340B Contract-Pharmacy Protection Statutes Survive: No §340B Preemption; No Takings, Contracts Clause, or Vagueness Violation

I. Introduction

AstraZeneca v. Murrill (consolidated with appeals by AbbVie-related entities and PhRMA) is the Fifth Circuit’s post-rehearing decision affirming Louisiana’s Act 358, a state statute that forbids drug manufacturers and distributors from “deny[ing], restrict[ing], prohibit[ing], or otherwise interfer[ing]” with a 340B covered entity’s acquisition of discounted drugs and delivery of those drugs to a covered entity’s contracted pharmacy.

The background conflict is familiar in modern 340B litigation: as contract-pharmacy utilization expanded under HRSA guidance, some manufacturers adopted policies limiting shipment or use of 340B-priced drugs through contract pharmacies. Louisiana—like other states—responded by regulating manufacturer conduct affecting the in-state distribution channel and pharmacy access.

The key issues were whether Act 358 (1) is preempted by the federal 340B statute, 42 U.S.C. § 256b, and (2) independently violates the Takings Clause (AbbVie), the Contracts Clause (AstraZeneca), or the Due Process vagueness doctrine (PhRMA). Louisiana also contested federal jurisdiction over the manufacturers’ preemption suits.

II. Summary of the Opinion

The Fifth Circuit held:

  • Jurisdiction: Federal-question jurisdiction exists because the manufacturers brought a classic Ex parte Young action seeking prospective injunctive/declaratory relief against state enforcement of an allegedly preempted law.
  • Preemption: Act 358 is not preempted by § 340B under field, conflict, or obstacle preemption.
  • Takings Clause: Act 358 effects neither a physical taking nor a regulatory taking.
  • Contracts Clause: Act 358 does not substantially impair AstraZeneca’s federal Pharmaceutical Pricing Agreement (PPA).
  • Vagueness: Act 358 is not unconstitutionally vague; “interfere” is sufficiently definite in context, and a facial challenge fails.

The court affirmed summary judgment for Louisiana and the intervenor, Louisiana Primary Care Association, and substantially adopted its earlier reasoning from AbbVie, Inc. v. Fitch.

III. Analysis

A. Precedents Cited (and How They Shaped the Decision)

1. The 340B framework and enforcement allocation

  • Astra USA, Inc. v. Santa Clara Cnty.: Used to describe § 340B’s “straightforward bargain,” confirm that Congress vested compliance oversight in HHS/HRSA, and characterize PPAs as “uniform agreements” that largely “recite” statutory obligations rather than negotiated private contracts. This framing supported the court’s later conclusion that Act 358 does not “rewrite” a bargained-for contract and that the federal statute’s content (and silences) must drive preemption analysis.

2. Agency-authority limits vs. state police power

  • Sanofi Aventis U.S. LLC v. U.S. Dep't of Health & Hum. Servs. and Novartis Pharms. Corp. v. Johnson: Central to the manufacturers’ best argument—if federal law is “silent” such that HHS cannot mandate delivery to unlimited contract pharmacies, why can a state? The Fifth Circuit treated these cases as holdings about delegated federal agency authority under § 340B, not as ceilings on state power. Congressional silence that constrains an agency does not, without “clear and manifest” intent, preempt traditional state regulation.

3. Fifth Circuit controlling (or near-controlling) authority

  • AbbVie, Inc. v. Fitch: The analytical anchor. The court deemed Mississippi’s materially indistinguishable 340B contract-pharmacy protection statute not preempted and not a taking. Although Fitch arose from a preliminary-injunction posture, the panel emphasized its reasoning turned on “pure questions of law” and adopted it on summary judgment. The opinion repeatedly treats Fitch as governing the core preemption and takings questions.

4. Other circuit support

  • Pharm. Rsch. & Mfrs. of Am. v. McClain: Cited for the proposition that § 340B is silent regarding pharmacies and delivery conditions, and for rejecting the claim that similar state laws set or enforce 340B pricing at the pharmacy level. This helped rebut AstraZeneca’s obstacle-preemption “pricing regulation” theory.

5. Presumption against preemption and preemption categories

  • Rice v. Santa Fe Elevator Corp. and Franks Inv. Co. LLC v. Union Pac. R.R. Co.: Supply the “presumption against preemption,” especially in areas of traditional state police power, which the court held includes public health and consumer protection—precisely the asserted bases for Act 358.
  • Crosby v. Nat'l Foreign Trade Council and Oneok, Inc. v. Learjet, Inc.: Cited for general supremacy and implied-preemption principles, framing the doctrinal toolkit.
  • English v. Gen. Elec. Co., City of El Cenizo v. Texas, and De Canas v. Bica: Support the field-preemption inquiry as one of congressional intent and caution against inferring “complete ouster of state power.”
  • O'Melveny & Myers v. FDIC: Used for the inference that issues left “unaddressed” in a detailed federal scheme are “presumably left” to state law—here, distribution logistics and the pharmacy role in dispensing.

6. Jurisdiction for affirmative preemption suits

  • Elam v. Kansas City Southern Railway Co.: Louisiana relied on Elam for the proposition that defensive preemption does not create federal jurisdiction. The Fifth Circuit distinguished it as involving preemption asserted defensively in a state-law action.
  • Ex parte Young, Shaw v. Delta Air Lines, Inc., and Planned Parenthood of Hou. & Se. Tex. v. Sanchez: Provide the rule that a plaintiff seeking to enjoin state regulation as preempted presents a federal question under 28 U.S.C. § 1331.
  • Reed v. Goertz: Cited to modernly restate the Ex parte Young doctrine for prospective relief.
  • New Orleans & Gulf Coast Ry. Co. v. Barrios: Cited to clarify that the Shaw principle concerns state action and does not automatically apply to purely private disputes.

7. Takings doctrine

  • Cedar Point Nursery v. Hassid: Provides the physical-taking baseline (government physical appropriation or invasion) and the regulatory-taking framework referencing Pa. Coal Co. v. Mahon and Penn Cent. Transp. Co. v. City of New York.

8. Contracts Clause test

  • Sveen v. Melin and Allied Structural Steel Co. v. Spannaus: Supply the two-step inquiry (substantial impairment; if so, reasonableness/legitimacy of means-ends) and an example of unconstitutional, unexpected, retroactive imposition that “rewrote” obligations.
  • Energy Rsrvs. Grp., Inc. v. Kan. Power & Light Co. and NextEra Energy Cap. Holdings, Inc. v. Lake: Emphasize that parties contract against a background expectation of regulation, especially in heavily regulated industries.
  • United Healthcare Ins. Co. v. Davis: Used for assessing reasonable expectations based on contract terms and regulatory backdrop.

9. Vagueness doctrine

  • United States v. Davis, United States v. Lanier, and Connally v. Gen. Constr. Co.: Provide the fundamental principle that vague laws violate due process by failing to give fair notice and inviting arbitrary enforcement.
  • Coates v. City of Cincinnati: Supplies the distinction between impermissible vagueness and “imprecise but comprehensible normative standard.”
  • Tex. Democratic Party v. Abbott and Groome Res. Ltd. v. Par. of Jefferson: Emphasize the high bar in civil contexts: the law must be so indefinite as to be “no rule at all.”
  • Vill. of Hoffman Estates v. Flipside, Hoffman Estates, Inc.: Provides the rule that, outside the First Amendment, a facial vagueness challenge requires vagueness in all applications.
  • Easom v. US Well Servs., Inc., United States v. Williams, and Yates v. United States: Support interpretive methods (including noscitur a sociis) used to narrow “interfere” by its statutory neighbors.
  • Echo Powerline, L.L.C. v. Occupational Safety & Health Rev. Comm'n: Reiterates that due process demands “fair and reasonable warning,” not “utmost precision.”

10. Federalism/Spending Clause caution (dicta with potential future significance)

  • Moyle v. United States: Quoted (Barrett, J., concurring) for the open question whether some Spending Clause statutes operating on private parties can preempt state law. The Fifth Circuit did not decide the question, but used it to counsel additional caution against expansive preemption findings here.
  • Landor v. La. Dep't of Corr. & Pub. Safety and McClure v. Ashcroft: Cited to reinforce avoidance of unnecessary constitutional decisions and the conceptual limits of Spending Clause “regulation.”

B. Legal Reasoning

1. Jurisdiction: offensive preemption claims belong in federal court

The court drew a bright line between (a) defensive preemption raised as a defense to state-law claims (which does not create federal-question jurisdiction under the well-pleaded complaint rule) and (b) an affirmative suit to enjoin state officials from enforcing an allegedly preempted statute. Because the manufacturers used preemption “as a sword,” their claims arose under federal law under Shaw v. Delta Air Lines, Inc. and fit the Ex parte Young framework.

2. Preemption: § 340B’s silences are space for state law, not implied federal exclusivity

(a) Field preemption

Following AbbVie, Inc. v. Fitch, the court catalogued what § 340B does regulate (ceiling prices; covered-entity eligibility; diversion/duplicate discount prohibitions; auditing; penalties; and manufacturer/wholesaler obligations to sell at the ceiling price), and contrasted it with what § 340B does not regulate: “the distribution of drugs to patients” and “the role of pharmacies in this distribution.” Because Act 358 operates in these traditional state domains, and because Congress did not “completely oust” state power, field preemption failed.

(b) Conflict and obstacle preemption

The court rejected several asserted conflicts:

  • No “expansion” of covered entities: Act 358 does not transform pharmacies into covered entities. Covered entities purchase and hold title to 340B drugs; contract pharmacies act as dispensing agents/intermediaries. Thus, requiring non-interference with delivery to a contract pharmacy is not requiring discounts to a new class of purchasers.
  • No clash with the federal enforcement scheme: Even if HHS is the “sole enforcer” of § 340B, Louisiana enforces Act 358—addressing a different subject (delivery interference) that § 340B does not address. The court conceptualized the regimes as operating in distinct spheres rather than overlapping enforcement of the same duty.
  • Not a price-control statute in disguise: The court rejected AstraZeneca’s premise that Act 358 “regulates pricing on its face.” It regulates manufacturer conduct that obstructs acquisition/delivery to contracted pharmacies. Any connection to discounted pricing is derivative of the covered entity’s existing federal entitlement; Act 358 does not set the price.

Critically, the court disentangled the manufacturers’ reliance on Sanofi Aventis U.S. LLC v. U.S. Dep't of Health & Hum. Servs. and Novartis Pharms. Corp. v. Johnson: those decisions limited HHS’s authority to mandate contract-pharmacy delivery under § 340B; they did not hold that state police-power regulation is preempted. Treating federal agency incapacity as an implied prohibition on states would invert the presumption against preemption by transforming silence into displacement.

3. Takings: Act 358 imposes non-interference, not compelled transfer or appropriation

AbbVie argued Act 358 is a physical taking because it effectively compels transfer of property to private parties. Relying on AbbVie, Inc. v. Fitch, the court characterized Act 358 as a “negative obligation of non-interference,” not a mandate to sell “larger quantities” at a discount beyond § 340B or to surrender possession without compensation. Manufacturers still receive payment at the 340B ceiling price for covered-entity purchases.

Under Penn Cent. Transp. Co. v. City of New York regulatory-taking factors (via Cedar Point Nursery v. Hassid), the court found: (1) limited economic impact because manufacturers still receive a “large percentage” of market price; (2) limited interference with reasonable expectations given decades of contract-pharmacy presence; and (3) a strong public character—facilitating access for low-income and rural patients.

4. Contracts Clause: no substantial impairment of the PPA

Applying Sveen v. Melin, the court ended at step one because there was no “substantial impairment.” Act 358 does not alter the terms of AstraZeneca’s PPA with HHS; it regulates covered entities’ arrangements with pharmacies, and the PPA is silent on delivery logistics. The court contrasted Louisiana’s statute with the retroactive, obligation-rewriting law struck down in Allied Structural Steel Co. v. Spannaus.

The court also relied on the regulated-industry baseline of Energy Rsrvs. Grp., Inc. v. Kan. Power & Light Co.: in a heavily regulated pharmaceutical market where state and federal oversight coexist, contracting parties cannot reasonably expect regulatory stasis—especially on matters (delivery conditions) the federal agreement does not address.

5. Vagueness: “interfere” is cabined by context and facial review is highly demanding

PhRMA’s facial vagueness challenge targeted “interfere.” The court used noscitur a sociis (supported by Easom v. US Well Servs., Inc., United States v. Williams, and Yates v. United States) to interpret “interfere” alongside “deny, restrict, prohibit,” narrowing it to obstructive conduct rather than routine auditing communications.

Independently, under Vill. of Hoffman Estates v. Flipside, Hoffman Estates, Inc., a facial challenge outside the First Amendment requires the statute to be vague in all applications. Because the statute clearly covers its core target—refusing to deliver 340B drugs to a covered entity’s contract pharmacy—the facial challenge failed.

C. Impact

1. Strengthening state authority in the “delivery logistics” gap

The most consequential doctrinal move is the court’s treatment of § 340B “silence” as an invitation for state supplementation in traditional police-power fields (public health, pharmacy regulation, consumer protection), not as an implied federal exclusivity principle. This cements a pathway for states to counter manufacturer contract-pharmacy restrictions through generally applicable distribution and pharmacy-access rules.

2. Aligning multi-circuit momentum while distinguishing federal-agency losses

Even though manufacturers prevailed in limiting HHS authority in Sanofi Aventis U.S. LLC v. U.S. Dep't of Health & Hum. Servs. and Novartis Pharms. Corp. v. Johnson, this opinion underscores that those victories do not automatically translate into preemption wins against states. The decision thus preserves a dual-regulatory reality: agency inability to mandate does not equal state inability to regulate.

3. Litigation posture: a clearer jurisdictional road map

By sharply distinguishing Elam v. Kansas City Southern Railway Co. from affirmative Ex parte Young preemption suits, the opinion reduces threshold uncertainty about bringing these challenges in federal court and may accelerate merits-focused litigation over similar state statutes.

4. Constitutional “backstops” narrowed

The rejection of Takings, Contracts Clause, and vagueness claims—each framed in ways common to regulated-industry disputes—signals a high bar for constitutional attacks on state 340B access laws when the state law is framed as non-interference in delivery and dispensing arrangements rather than compelled price-setting or compelled transfers.

5. A notable Spending Clause hint (without a holding)

The court’s discussion of Moyle v. United States flags (but does not resolve) whether and how Spending Clause statutes can preempt state law, suggesting future preemption disputes may increasingly turn on the constitutional source of federal authority as well as statutory text.

IV. Complex Concepts Simplified

  • 340B “covered entities” vs. contract pharmacies: Covered entities (clinics/hospitals serving vulnerable populations) buy drugs at the 340B ceiling price and retain title. Contract pharmacies typically dispense those drugs to patients on the covered entity’s behalf; they are not transformed into covered entities merely by dispensing.
  • Field vs. conflict vs. obstacle preemption: Field preemption asks whether Congress meant to occupy an entire regulatory area. Conflict preemption asks whether compliance with state and federal law is impossible or whether the state law obstructs federal objectives (obstacle preemption).
  • Why federal “silence” matters: If Congress regulates many details but leaves a topic unaddressed (here, delivery and pharmacy logistics), courts often treat that as leaving room for state law rather than implying a hidden ban on state regulation—especially in traditional state police-power areas.
  • Physical vs. regulatory takings: A physical taking is a compelled occupation or appropriation. A regulatory taking is a restriction that goes “too far” under the Penn Central balancing test.
  • Facial vagueness challenges: Outside free-speech contexts, a plaintiff generally must show the law is vague in all applications; if the law clearly covers a central example of prohibited conduct, the facial challenge usually fails.

V. Conclusion

AstraZeneca v. Murrill entrenches a Fifth Circuit rule that state laws like Louisiana’s Act 358—aimed at preventing manufacturer interference with a covered entity’s use of contract pharmacies—fit within traditional state police powers and are not preempted by § 340B’s pricing-and-eligibility scheme. The court further holds that such statutes, framed as non-interference requirements, do not amount to takings, do not substantially impair federal pricing agreements under the Contracts Clause, and are not void for vagueness.

In practical terms, the decision validates a state-centered regulatory response to the contract-pharmacy controversy left unresolved by § 340B’s text and by federal courts’ limitations on HHS’s power—shifting the principal battleground for contract-pharmacy access from federal agency action to state legislative design and state enforcement.